National Pharmaceutical Pricing Authority (NPPA) has hiked the prices of as many as 186 formulation packs including monocomponent insulin, some popular combination drugs involving ibuprofen and paracetamol. The price regulator also brought down the prices of two formulation packs, both from sanofi aventis.

The price hike, which may bring cheers to many manufacturers hit by high costs of inputs, mostly ranged around 10 per cent. The formulation packs, whose prices were increased, included those from companies like sanofi aventis, Pfizer Products India, RPG Life Sciences and Eli Lilly.

According to the notification by the NPPA dated August 6, many of the combination drugs involving popular drugs like ibuprofen and paracetamol became costlier. The prices of 13 packs of monocomponent insulin from Pfizer were hiked. novalgin tablets and injections from sanofi, spirolactone tablets (four packs) from RPG Life Sciences and six depo-medrol products from Pfizer were also among the formulations whose prices went up.

Other formulations which became costlier include dexibuprofen+paracetamol combination, ibuprofen, pheniramine maleate tablets, cefadroxyl tablets, two frusemide combinations, betamethasone, ciprofloxacin combination, five dexamethasone combination drugs, dextropropoxyphene, two doxycycline combinations, ibuprofen capsule, two metronidazole combination packs, five multivitamin formulations, two prednisolone injections, three dextropropoxyphane combination packs and trimethoprin.